Several trials have shown the beneficial effect of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced non-small cell lung cancer patients (NSCLC) harboring activating EGFR mutations leading to the adoption of EGFR-TKI as standard treatment in this population [3, 4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.